Division of Pharmacology, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey.
Bioorg Med Chem. 2012 Oct 1;20(19):5992-6002. doi: 10.1016/j.bmc.2012.06.054. Epub 2012 Jul 11.
A hierarchical in silico screening procedure using the crystal structure of an agonist bound chimeric α7/Ls-AChBP protein was successfully applied to both proprietary and commercial databases containing drug-like molecules. An overall hit rate of 26% (pK(i) ≥5.0) was obtained, with an even better hit rate of 35% for the commercial compound collection. Structurally novel and diverse ligands were identified. Binding studies with [(3)H]epibatidine on chimeric α7/5-HT(3) receptors yielded submicromolar inhibition constants for identified hits. Compared to a previous screening procedure that utilized the wild type Ls-AChBP crystal structure, the current study shows that the recently obtained α7/Ls-AChBP chimeric protein crystal structure is a better template for the identification of novel α7 receptor ligands.
采用与激动剂结合的嵌合α7/Ls-AChBP 蛋白晶体结构的分层计算机筛选程序,成功地应用于含有类药性分子的专有和商业数据库。获得了 26%的总命中率(pK(i)≥5.0),商业化合物库的命中率甚至更好,达到 35%。鉴定出具有新颖结构和多样性的配体。用[(3)H]epibatidine 进行的嵌合α7/5-HT(3)受体结合研究,对鉴定出的命中物产生了亚微摩尔抑制常数。与先前使用野生型 Ls-AChBP 晶体结构的筛选程序相比,本研究表明,最近获得的α7/Ls-AChBP 嵌合蛋白晶体结构是鉴定新型α7 受体配体的更好模板。